Velocity Pharmaceutical Development

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Regulatory Clearance for Initiating Phase II Study with VPD-737 in Prurigo Nodularis

South San Francisco, California – June 23, 2013

Velocity Pharmaceutical Development, LLC (“VPD”) and Tigercat Pharma, Inc., (“Tigercat”) announced today that they have met all regulatory requirements from Germany’s BfArM to initiate a Phase II clinical trial of VPD-737 (serlopitant) in patients with prurigo nodularis. Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus.

“Prurigo nodularis is a chronic, debilitating dermatological condition that frequently leads to permanent changes to the skin and prevents patients from living a normal and productive lifestyle. Unfortunately, current therapy options for this orphan disease remain poor thus the unmet medical need for a successful treatment alternative for prurigo nodularis and chronic pruritus remains high” said Prof. Dr. Sonja Ständer, the Principle Investigator for the study. Dr. Ständer is professor for Dermatology and Neurodermatology at the Department of Dermatology, and head of the Interdisciplinary Competence Center Chronic Pruritus of the University Hospital Münster, Germany.

“We are excited about Tigercat achieving another important milestone by starting this new clinical trial and look forward to share top-line results from this study and our chronic pruritus trial in early 2015”, said Dr. Edward Schnipper, Tigercat’s Chief Medical Officer.

The trial is a double-blind, placebo-controlled Phase II study in patients with prurigo nodularis, an orphan disease. The study is designed to determine the safety, tolerability, and efficacy of VPD-737, an NK-1 receptor antagonist, and will be conducted at four sites in Germany.

VPD-737 (serlopitant) was exclusively licensed to VPD from Merck in 2012.

About Tigercat Pharma, Inc.

Tigercat Pharma, Inc., is a largely “virtual” company which was created to hold

the ownership of the VPD-737 development program. Tigercat is funded by

Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC. The VPD-737

development program is managed under contract by VPD.

 

About Velocity Pharmaceutical Development, LLC

VPD is a pharmaceutical development organization dedicated to rapidly advancing

promising drug candidates to clinical proof of concept using a highly virtual

management model. VPD seeks to acquire promising drug candidates, generally

within a year of their entering human clinical trials or after initial human clinical

data have been generated. VPD then manages a development program for each drug

candidate intended to generate convincing human proof of concept data (generally

by conducting a phase 2 clinical trial). Following successful human proof of concept,

VPD then seeks a large pharmaceutical company acquirer for each program. VPD

is staffed by a seasoned team of clinical drug developers with expertise identifying

attractive drug candidates, target markets, and designing and managing outsourced

clinical trials. This expert team manages multiple single asset companies to remove

the costly overhead and misaligned incentives present in traditional biotechnology

company structures. VPD believes this new capital-efficient model will yield

attractive new drugs to treat patients with significant unmet clinical needs. The

company is located in South San Francisco, California. More information is available

at www.vpd.net.

 

About Velocity Pharmaceutical Holdings, LLC

Velocity Pharmaceutical Holdings, LLC, is an entity funded by CMEA Capital that

makes investments in highly virtual, project-focused pharmaceutical development

companies that are managed by Velocity Pharmaceutical Development, LLC. More

information is available at www.vpd.net and www.cmea.com.

 

About Remeditex Ventures, LLC

Remeditex is a company that seeks to develop opportunities in need of commercial

validation, guidance, and capital. Its mission is to develop early stage biomedical

science and make Texas and Colorado a preferred location for biotechnology

companies, venture capitalists, and entrepreneurs by accelerating the pace of

commercialization of biomedical research; help create and support a thriving

biotechnology industry; attract biotech venture capital to Texas and Colorado; and

achieve significant returns to support the next generation of promising science.

More information is available at www.remeditex.com.

 

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

 

Contact

Leslie Loven

1-415-524-7326

leslie@vpd.net